PaulYangMDPhD

Ophthalmology • Portland, OR

Cataract Related, Retinal Disease, Uveitis

Associate Professor, Ophthalmic Genetics & Ocular Immunology

Join to view full profile

Dr. Yang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yang's full profile

Already have an account?

Office
545 SW Campus Dr
Portland, OR 97239
Phone+1 503-494-8311

Education & Training

Oregon Health Science University HospitalFellowship, Ophthalmic Genetics and Inherited Retinal Degeneration, 2012 - 2013
Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolFellowship, Ocular Immunology/Uveitis, 2011 - 2012
University of Utah HealthFellowship, Surgical Retina and Vitreous, 2010 - 2011
University of Utah HealthResidency, Ophthalmology, 2007 - 2008
University of Utah HealthInternship, Internal Medicine, 2006 - 2007
Geisel School of Medicine at DartmouthClass of 2006
DartmouthPhD, Neurophysiology , 1998 - 2003

Certifications & Licensure

OR State Medical License 2012 - 2025
MA State Medical License 2011 - 2015
UT State Medical License 2007 - 2014
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS) Start of enrollment: 2015 May 01
Completed
Phase 1, Phase 2

Publications & Presentations

PubMed

62 citations
Advancing Clinical Trials for Inherited Retinal Diseases: Recommendations from the Second Monaciano Symposium
Debra A. Thompson, Alessandro Iannaccone, Robin R. Ali, Vadim Y. Arshavsky, Isabelle Audo
Translational Vision Science & Technology. 2020-06-03
41 citations
Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.
Mark E. Pennesi, Richard G. Weleber, Paul Yang, Chris Whitebirch, Beverly Thean
Human Gene Therapy. 2018-12-13
3 citations
Variable expressivity of BEST1-associated autosomal dominant vitreoretinochoroidopathy (ADVIRC) in a three-generation pedigree.
Mariana Matioli da Palma, Mauricio E Vargas, Amanda Burr, Rui Chen, Mark E. Pennesi
BMJ Open Ophthalmology. 2021-10-21

Press Mentions

Gene Therapy Allows Teen to See Snowflakes for the First TimeApril 5th, 2023
Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual MeetingMay 4th, 2022
TeamedOn and AGTC Announce a Licensing Agreement Advancing X-linked Retinoschisis Gene Therapy ProgramApril 13th, 2021
Join now to see all